{"organizations": [], "uuid": "df2ce550e04494361558f702fdadd971d7930dc6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/08/19/idUSB8N10U02S20150819", "country": "US", "title": "BRIEF-Corbus Pharmaceuticals says Resunab granted fast track status by FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "BRIEF-Corbus Pharmaceuticals says Resunab granted fast track status by FDA | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-08-19T15:45:00.000+03:00", "replies_count": 0, "uuid": "df2ce550e04494361558f702fdadd971d7930dc6"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/08/19/idUSB8N10U02S20150819", "ord_in_thread": 0, "title": "BRIEF-Corbus Pharmaceuticals says Resunab granted fast track status by FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Aug 19 Corbus Pharmaceuticals Holdings Inc :\n* Corbus Pharmaceuticals says investigational drug Resunab granted fast track status by FDA for the treatment of systemic sclerosis\n* Corbus Pharmaceuticals says scheduled to begin enrollment and dosing in its phase 2 study of Resunab this quarter Source text for Eikon:\nFurther company coverage:", "external_links": [], "published": "2015-08-19T15:45:00.000+03:00", "crawled": "2015-08-19T14:53:18.841+03:00", "highlightTitle": ""}